Trkla Co-Authors ABA Business Law Section Whitepaper Providing a Framework for Regulating Cryptocurrency and Digital Assets
March 13, 2019
American Bar Association
Partner Kathryn Trkla co-authored a first of its kind white paper on the regulation of cryptocurrencies and digital assets at the federal and state level. The white paper, “Digital and Digitized Assets: Federal and State Jurisdictional Isssues” was published by the ABA’s Business Law Section and provides background on digital and blockchain technologies as as well as analyses of the application of the Commodity Exchange Act, federal securities laws and others to transactions using cryptocurrencies and digital assets, surveys of state law regulating transactions in digital assets and cryptocurrencies and a survey of approaches in foreign jurisdictions.
Trkla is vice-chair of the ABA’s Derivatives & Futures Law Committee and chairs of the Innovative Digitized Products and Processes Subcommittee of the Business Law Section, which issued the white paper.
Trkla is vice-chair of the ABA’s Derivatives & Futures Law Committee and chairs of the Innovative Digitized Products and Processes Subcommittee of the Business Law Section, which issued the white paper.
People
Related News
August 13, 2025
In the News
Leigh Riley on Elevating Partner Development with Foley's PEAK Program – 'We can't stop learning'
Foley & Lardner LLP partner Leigh Riley appeared on the Big Law Life podcast to share how Foley is redefining professional development to meet the needs of the firm's partners and the demands of modern legal practice.
August 8, 2025
In the News
Gregory Husisian and David Simon Uncover the High Stakes of Tariff Evasion
Foley & Lardner LLP partners Gregory Husisian and David Simon are featured for their insights on how the U.S. government is cracking down on tariff evaders in the Newsweek article, "America Is Making Billions From Catching 'Tariff Cheaters.'"
August 7, 2025
In the News
Kyle Faget Weighs in on Trump Pharma Tariffs
Foley & Lardner LLP partner Kyle Faget assessed the Trump administration's implementation of import tariffs on the pharmaceutical industry in the Pharma Life Sciences article, "Trump's pharma import tariffs threaten drug pricing, generics."